

PCT COOPERATION TREATY

PCT

NOTIFICATION OF ELECTION

(PCT Rule 61.2)

From the INTERNATIONAL BUREAU

To:

Commissioner
US Department of Commerce
United States Patent and Trademark
Office, PCT
2011 South Clark Place Room
CP2/5C24
Arlington, VA 22202
ETATS-UNIS D'AMERIQUE

in its capacity as elected Office

Date of mailing (day/month/year) 24 November 2000 (24.11.00)	
International application No. PCT/US99/05751	Applicant's or agent's file reference UD1561A PCT
International filing date (day/month/year) 16 March 1999 (16.03.99)	Priority date (day/month/year)
Applicant SMALL, Parker et al	

1. The designated Office is hereby notified of its election made:

☒ in the demand filed with the International Preliminary Examining Authority on:

16 October 2000 (16.10.00)

☐ in a notice effecting later election filed with the International Bureau on:
2. The election ☒ was
☐ was not

made before the expiration of 19 months from the priority date or, where Rule 32 applies, within the time limit under Rule 32.2(b).

<p>The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland</p> <p>Facsimile No.: (41-22) 740.14.35</p>	<p>Authorized officer</p> <p>Zakaria EL KHODARY</p> <p>Telephone No.: (41-22) 338.83.38</p>
--	---

PATENT COOPERATION TREATY

PCT

From the INTERNATIONAL BUREAU

**NOTIFICATION CONCERNING
AMENDMENTS OF THE CLAIMS**

(PCT Rule 62 and
Administrative Instructions, Section 417)

To:

Commissioner
US Department of Commerce
United States Patent and Trademark
Office, PCT
2011 South Clark Place Room
CP2/5C24
Arlington, VA 22202
ETATS-UNIS D'AMERIQUE
in its capacity as International Preliminary Examining Authority

Date of mailing (day/month/year)
24 November 2000 (24.11.00)

International application No.
PCT/US99/05751

International filing date (day/month/year)
16 March 1999 (16.03.99)

Applicant
UNIVERSITY OF FLORIDA et al

The International Bureau hereby informs the International Preliminary Examining Authority that no amendments under Article 19 have been received by the International Bureau (Administrative Instructions, Section 417).

<p>The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland</p> <p>Facsimile No. (41-22) 740.14.35</p>	<p>Authorized officer Zakaria EL KHODARY</p> <p>Telephone No. (41-22) 338.83.38</p>
--	--

PATENT COOPERATION TREATY

PCT

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

REC'D 27 FEB 2001

Applicant's or agent's file reference UF-156IA PCT		FOR FURTHER ACTION See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)	
International application No. PCT/US99/05751	International filing date (day/month/year) 16 MARCH 1999	Priority date (day/month/year) NONE	
International Patent Classification (IPC) or national classification and IPC IPC(7): G03F7/00 and US Cl.: 435/5			
Applicant UNIVERSITY OF FLORIDA			

1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.

2. This REPORT consists of a total of 3 sheets.

☐ This report is also accompanied by ANNEXES, i.e., sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority. (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).

These annexes consist of a total of 0 sheets.

3. This report contains indications relating to the following items:

- I ☒ Basis of the report
- II ☐ Priority
- III ☐ Non-establishment of report with regard to novelty, inventive step or industrial applicability
- IV ☐ Lack of unity of invention
- V ☒ Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
- VI ☐ Certain documents cited
- VII ☐ Certain defects in the international application
- VIII ☐ Certain observations on the international application

Date of submission of the demand 16 OCTOBER 2000	Date of completion of this report 30 JANUARY 2001
Name and mailing address of the IPEA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231	Authorized officer ROBERT A. ZEMAN
Facsimile No. (703) 305-3230	Telephone No. (703) 308-0196

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.

PCT/US99/05751

I. Basis of the report**1. With regard to the elements of the international application:***☒ the international application as originally filed☒ the description:

pages 1-27

pages NONE

pages NONE

, as originally filed
, filed with the demand
, filed with the letter of☒ the claims:

pages 28-30

pages NONE

pages NONE

pages NONE

, as originally filed
, as amended (together with any statement) under Article 19
, filed with the demand
, filed with the letter of☒ the drawings:

pages 1-2

pages NONE

pages NONE

, as originally filed
, filed with the demand
, filed with the letter of☒ the sequence listing part of the description:

pages NONE

pages NONE

pages NONE

, as originally filed
, filed with the demand
, filed with the letter of**2. With regard to the language, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.**
These elements were available or furnished to this Authority in the following language _____ which is:☐ the language of a translation furnished for the purposes of international search (under Rule 23.1(b)).☐ the language of publication of the international application (under Rule 48.3(b)).☐ the language of the translation furnished for the purposes of international preliminary examination (under Rules 55.2 and/or 55.3).**3. With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:**☐ contained in the international application in printed form.☐ filed together with the international application in computer readable form.☐ furnished subsequently to this Authority in written form.☐ furnished subsequently to this Authority in computer readable form.☐ The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.☐ The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.**4. ☒ The amendments have resulted in the cancellation of:**☒ the description, pages NONE☒ the claims, Nos. NONE☒ the drawings, sheets/fig. NONE**5. ☐ This report has been drawn as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed, as indicated in the Supplemental Box (Rule 70.2(c)).****

* Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report since they do not contain amendments (Rules 70.16 and 70.17).

** Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report.

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.

PCT/US99/05751

V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. statement

Novelty (N)

Claims 1-15 YESClaims NONE NO

Inventive Step (IS)

Claims 1-15 YESClaims NONE NO

Industrial Applicability (IA)

Claims 1-15 YESClaims NONE NO

2. citations and explanations (Rule 70.7)

Claims 1-15 meet the criteria set out in PCT Article 33(2)-(4), because the prior art cited in the search report does not teach or fairly suggest the method or the device recited in the claimed invention.

----- NEW CITATIONS -----

NONE

PCT

INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference UD1561A PCT	FOR FURTHER ACTION see Notification of Transmittal of International Search Report (Form PCT/ISA/220) as well as, where applicable, item 5 below.	
International application No. PCT/US 99/ 05751	International filing date (day/month/year) 16/03/1999	(Earliest) Priority Date (day/month/year)
Applicant UNIVERSITY OF FLORIDA et al.		

This International Search Report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.

This International Search Report consists of a total of 3 sheets.

☒ It is also accompanied by a copy of each prior art document cited in this report.

1. Basis of the report

- a. With regard to the **language**, the international search was carried out on the basis of the international application in the language in which it was filed, unless otherwise indicated under this item.

☐ the international search was carried out on the basis of a translation of the international application furnished to this Authority (Rule 23.1(b)).

- b. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international search was carried out on the basis of the sequence listing :

☐ contained in the international application in written form.

☐ filed together with the international application in computer readable form.

☐ furnished subsequently to this Authority in written form.

☐ furnished subsequently to this Authority in computer readable form.

☐ the statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.

☐ the statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished

2. ☐ **Certain claims were found unsearchable** (See Box I).

3. ☐ **Unity of invention is lacking** (see Box II).

4. With regard to the **title**,

☒ the text is approved as submitted by the applicant.

☐ the text has been established by this Authority to read as follows:

5. With regard to the **abstract**,

☒ the text is approved as submitted by the applicant.

☐ the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box III. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority.

6. The figure of the **drawings** to be published with the abstract is Figure No.

☒ as suggested by the applicant.

☐ because the applicant failed to suggest a figure.

☐ because this figure better characterizes the invention.

1
☐ None of the figures.

INTERNATIONAL SEARCH REPORT

International Application No.

P 99/05751

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12Q1/44 G01N33/68 G01N33/84

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12Q G01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
E	✓ US 5 910 421 A (SMALL JR PARKER A ET AL) 8 June 1999 (1999-06-08) the whole document	1-15
A	✓ RAPHAEL GD ET AL: "The pathophysiology of rhinitis. V. Sources of protein in allergen-induced nasal secretions" J. ALLERGY CLIN. IMMUNOL., vol. 88, no. 1, July 1999 (1999-07), pages 33-42, XP000852998 cited in the application abstract	1-15

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

° Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

25 November 1999

Date of mailing of the international search report

07/12/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Pellegrini, P

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 99/05751

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A ✓	LANS DM ET AL: "Nasal eosinophilia in allergic and nonallergic rhinitis: usefulness of the nasal smear in the diagnosis of allergic rhinitis" ALLERGY PROC, vol. 10, no. 4, August 1989 (1989-08), pages 275-280, XP000852703 abstract -----	1-15
A ✓	NACLERIO R M ET AL: "Mediator release after nasal airway challenge with allergen." AMERICAN REVIEW OF RESPIRATORY DISEASE, (1983 OCT) 128 (4) 597-602. , XP000852716 abstract -----	1-15
A ✓	US 4 645 842 A (COREY PAUL F ET AL) 24 February 1987 (1987-02-24) cited in the application column 3, line 51-54 column 21, line 19-22 -----	1-15

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 99/05751


Patent document cited in search report		Publication date	Patent family member(s)	Publication date
US 5910421	A	08-06-1999	NONE	
US 4645842	A	24-02-1987	AT 64382 T	15-06-1991
			AU 558425 B	29-01-1987
			AU 4072485 A	10-10-1985
			CA 1267500 A	03-04-1990
			EP 0157327 A	09-10-1985
			ES 541871 A	16-06-1986
			FI 851356 A,B,	07-10-1985
			IE 57919 B	19-05-1993
			IL 74645 A	31-10-1988
			JP 1436349 C	25-04-1988
			JP 60260558 A	23-12-1985
			JP 62041710 B	04-09-1987
			NO 851226 A	07-10-1985
			US 4774340 A	27-09-1988
			US 4704460 A	03-11-1987



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7 : C12Q 1/44, G01N 33/68, 33/84		A1	(11) International Publication Number: WO 00/55359
			(43) International Publication Date: 21 September 2000 (21.09.00)
(21) International Application Number: PCT/US99/05751 (22) International Filing Date: 16 March 1999 (16.03.99) (71) Applicant (for all designated States except US): UNIVERSITY OF FLORIDA [US/US]; 1938 West University Avenue, Gainesville, FL 32603-1735 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): SMALL, Parker [US/US]; 3454 NW 12th Avenue, Gainesville, FL 32605 (US). HUANG, Shih-Wen [US/US]; 2821 NW 58th Boulevard, Gainesville, FL 32606 (US). (74) Agent: BENCEN, Gerard, H.; Bencen & Van Dyke, P.A., 1630 Hillcrest Street, Orlando, FL 32803 (US).		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published With international search report.	
		CTS Date received 10/1/00 Docketed 10/3/00 By MK Timely response due _____ Last date to file response _____	

(54) Title: RAPID DIAGNOSTIC METHOD FOR DISTINGUISHING ALLERGIES AND INFECTIONS



(57) Abstract

A method and device for rapidly, non-invasively and inexpensively differentiating between allergic rhinitis, upper respiratory tract viral infection and bacterial sinusitis, comprising a support strip upon which is fixed discrete indicators of pH, protein content, nitrite content, esterase activity, and eosinophil content of a sample with which said reagent test strip is contacted. Contact of a nasal secretion with the device of this invention permits differentiation between allergic, bacterial and viral conditions, based on pH, protein content, esterase activity, nitrite content, and eosinophil content.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

DESCRIPTIONRAPID DIAGNOSTIC METHOD FOR DISTINGUISHING ALLERGIES AND
INFECTIONS

5

Background of the InventionI. Field of the Invention:

This invention is a rapid and simple method for the differential diagnosis of allergies,
10 sinusitis and upper respiratory tract infections. The method involves the use of either
commercially available or novel, specifically adapted, indicator or reagent test strips which
are contacted with nasal secretions. Based on the differential read-out from the indicator
strip, and a measure of eosinophil infiltration in the nasal secretion, a user of the strip is
able to determine, with the assistance of a scoring method disclosed herein, whether an
15 allergic condition or an infection is the cause of the respiratory discomfort.

II. Background:

It is common for patients afflicted with respiratory discomfort to seek the advice of a
20 clinician in an effort to minimize or overcome their discomfort. Such discomfort generally
is attributable to one of the following etiologies: allergic reactions, viral upper respiratory
tract infections (URIs), or bacterial infections which can produce sinusitis. However, the
clinician presented with such a patient typically has the daunting task of determining which
of these three principal etiologies is responsible for the discomfort experienced by a
25 particular patient. The danger

inherent in a mis-diagnosis can be quite severe. For example, should the clinician
incorrectly diagnose an allergy as sinusitis, a course of antibiotics would typically be
prescribed. Naturally, such treatment would do little to alleviate the allergic discomfort
being experienced by the patient while at the same time, the patient is exposed to an
30 antibiotic to which there is a possibility of raising a resistant bacterial infection. Should
this occur, a problem much more severe than the original allergic condition will have been
unwittingly engendered. The prevalence of antibiotic-resistant strains on a global scale
due to the over-prescription of antibiotics has become an increasingly recognized problem
(Service, R.F., 1995).

In the foregoing example, the availability of a rapid and simple differential diagnostic method would, instead of resulting in a compounded problem, result in the simple recommendation by the clinician that the patient adhere to a course of anti-histamine treatment, allergen avoidance, and/or a regimen of toleragenic desensitization. Unfortunately, however, to date, there is no such simple procedure which will provide the clinician with the necessary differential diagnosis. The accepted method of diagnosis for bacterial sinusitis is expensive radiologic imaging (typically X-ray or CT-scan) of the patients sinuses (see Katz et al., 1995).

10

Many scientific articles have appeared addressing one or another of the various etiologies of respiratory discomfort. However, no rapid, inexpensive differential diagnostic method has been found. Thus, for example, Wang *et al.*, *Correlations between Complaints, Inflammatory Cells and Mediator Concentrations in Nasal Secretions after Nasal Allergen Challenge and during Natural Allergen Exposure*, Int. Arch. Allergy Immunology 1995; 106:278-285, disclosed a method of using a nasal microsuction technique. They showed that nasal allergen challenge (NAC) of asymptomatic (out of season) seasonal allergic rhinitis patients results in immediate (5 minutes) increases in histamine, leukotriene C4 (LTC4), and tryptase, with a more gradual (one hour post NAC) and prolonged increase in eosinophil and eosinophil cationic protein (ECP) concentration in nasal secretions. By contrast, in symptomatic (in season allergic rhinitis) patients, high concentrations of eosinophils, ECP, LTC4 and histamine, but not tryptase, were observed. It was concluded that allergic rhinitis is a chronic inflammation of the nasal mucosa, and that infiltration of eosinophils and release of late-phase inflammatory mediators are the predominant pathophysiologic markers. However, this publication neither teaches nor suggests that these observations can be applied to distinguish patients suffering from an allergic condition as opposed to an infection. In addition, the methods used by these authors are laborious and time-consuming and do not involve the use of reagent test strips. Sigurs *et al.*, *Eosinophil cationic protein in nasal secretion and in serum and myeloperoxidase in serum in respiratory syncytial virus bronchiolitis: relation to asthma and atopy*, Acta Paediatr 1994; 83:1151-5, concluded that it is not possible to predict, from eosinophil cationic protein/albumin ratios in nasal secretions or from ECP and myeloperoxidase concentrations in serum, whether children with respiratory syncytial virus (RSV) bronchiolitis would develop asthma. The publication provides no teaching or suggestion

of a method which can easily distinguish patients suffering from an allergic condition as opposed to an infection. The methods used by these authors are laborious and time-consuming and do not involve the use of reagent test strips. Okuda *et al.*, *A Novel Method of Counting Eosinophils in Nasal Secretion of*

- 5 *Allergic Rhinitis by Hemocytometric Method*, Int. Arch. Allergy Immunol. 1994; 104 (suppl. 1):6, disclosed a rapid method for quantitating the number of eosinophils in nasal secretions as a method for diagnosis of allergic rhinitis. The method involves preparation of a solubilized sample of nasal secretion and counting of whole eosinophils. There is no mention of reagent test strips and there is no mention of a method for distinguishing
- 10 patients suffering from an allergic condition as opposed to an infection.

Kowalski *et al.*, *Neutrophil chemotactic activity (NCA) in nasal secretions from atopic and nonatopic subjects*, Allergy 1993; 48:409-414, reported that basal nasal secretions of both healthy persons and patients with chronic rhinitis contain significant chemotactic activity

15 to neutrophils. The study also reports that there is an increase in protein content of nasal secretions in patients with perennial allergic rhinitis (AR) following challenge with an antigen. There is no mention of reagent test strips and there is no mention of a method for distinguishing patients suffering from an allergic condition as opposed to an infection.

- 20 Igarashi *et al.*, *Analysis of nasal secretions during experimental rhinovirus upper respiratory infections*, J. Allergy Clin. Immunol. 1993; 92:722-731, studied patients with allergic rhinitis or control subjects inoculated with rhinovirus. Nasal lavage samples pre- and post-infection were analyzed for protein and mast cell mediators. It was found that total protein (including the plasma proteins albumin and IgG and the glandular proteins
- 25 lactoferrin, lysozyme and secretory IgA) increased post-infection, predominantly due to increased vascular permeability. It was also found that the allergic subjects had fewer symptoms, but greater vascular permeability and greater histamine secretion than control subjects post-rhinovirus infection. Protein was determined by the bicinchoninic acid protein assay (Pierce Chemical Co.) on aliquots of nasal lavage. It is noted at several
- 30 points in the publication that the symptoms of rhinovirus infected patients and patients with nasal allergic reactions are similar, thus teaching away from the possibility that a simple nasal secretion assay method could be used to distinguish these conditions. Inasmuch as this study is directed at determining the differences in nasal secretions between rhinovirus infected normal or allergic individuals, the study addresses a different

problem than that addressed by the instant invention, which is a method for measuring the differences in nasal secretions of patients infected with a rhinovirus, for example, and a patient not infected with a rhinovirus but suffering from allergic rhinitis. The methods used by these authors are laborious and time-consuming and do not involve the use of reagent test strips.

Sperber *et al.*, *In vivo detection of a novel macrophage-derived protein involved in the regulation of nasal mucus-like glycoconjugate secretion*, J. Allergy Clin. Immunol. 1993; 92:581-588, disclosed a study directed at characterization of a novel 68 Kd nasal mucus secretagogue (NMS-68) released by monocytes. Inasmuch as this protein was found to be present in nasal tissue of patients with allergic and non-allergic rhinitis, it does not appear to provide a method for distinguishing between these conditions (although the baseline level of this protein is more elevated in the allergic patients). Reagent test strips were not used in this study.

Knani *et al.*, *Indirect evidence of nasal inflammation assessed by titration of inflammatory mediators and enumeration of cells in nasal secretions of patients with chronic rhinitis*, J. Allergy Clin. Immunol. 1992; 90:880-889, examined the nasal lavage cells and six inflammatory mediators released in nasal secretions of four groups of patients with perennial rhinitis and a control group. It was found that patients with symptomatic allergic rhinitis had increased levels of eosinophils, as well as of eosinophil protein X (EPX), LTC₄/D₄, tryptase, MPO and PGD₂. Patients with non-allergic rhinitis were found to have increased neutrophil, tryptase, MPO and EPX concentrations. These measurements provided indirect evidence of nasal inflammation. However, there was no analysis of differences between the nasal secretions of rhinitis patients and patients suffering, for example, from a rhinoviral infection or a bacterial sinus infection.

Klementsson *et al.*, *Eosinophils, secretory responsiveness and glucocorticoid-induced effects on the nasal mucosa during a weak pollen season*, Clinical and Experimental Allergy 1991; 21:705- 710, analyzed the eosinophil influx, the concentration of ECP and secretory responsiveness following methacholine challenge in nasal lavage samples of patients with allergic rhinitis. There was no concurrent analysis of nasal secretions from patients with bacterial sinus or viral infections, and reagent test strips were not employed.

Gordon *et al.*, *The pathophysiology of rhinitis*, J. Allergy Clin. Immunol. 1991; 88:33-42, challenged patients with seasonal rhinitis on one side of the nose with an allergen and nasal secretions from both sides of the nose were analyzed for protein and mediators. There was no concurrent analysis of nasal secretions from patients with bacterial or viral infections, and reagent test strips were not employed.

Cohen, R. A, and Brestel, E. P., *Nasal secretory response to allergen provocation*, 1988; 18:435-443, analyzed nasal lavage samples from ragweed-sensitive and control subjects following ragweed pollen challenge. The study revealed no increase in total protein, albumin, potassium, lysozyme activity or peroxidase activity in the control subjects. There were increases in all of these constituents in the ragweed-sensitive subjects. These constituents were assayed by dye binding (Bradford), rocket immunoelectrophoresis, absorption spectroscopy, ABTS (Sigma Chemical Co.) oxidation, and radial diffusion, respectively. Use of reagent test strips is neither taught nor suggested, nor is there a concomitant analysis of these constituents in bacterially or viral infected, no-allergic subjects.

Liu *et al.*, *Injurious effect of eosinophil extract on the human nasal mucosa*, Rhinology 1988; 26:121-132, attempted to elucidate the role of eosinophils in nasal secretions of allergic subjects. These authors conclude that the eosinophil extracts tested may actually be harmful to the function of human nasal mucosa. Use of reagent test strips is neither taught nor suggested, nor is there a concomitant analysis of these constituents in infected subjects.

Anderson *et al.*, *Allergen-induced nasal hyperactivity appears unrelated to the size of the nasal and dermal immediate allergic reaction*, Allergy 1987. 42:631-637, analyzed "priming", in which nasal lavage samples from hay fever patients were tested following an initial and a re-challenge with allergen. The biochemical parameter used as the measure of the allergic reaction was TAME-esterase via a radiochemical method (release of tritium labeled methanol from the synthetic substrate H3-TAME). Use of reagent test strips is neither taught nor suggested, nor is there a concomitant analysis of these constituents in infected subjects.

Settipane, G. A, and Klein, D. E., *Non Allergic Rhinitis: Demography of Eosinophils in Nasal Smear, Blood Total Eosinophil Counts and IgE Levels*, NER Allergy Proc.1985; 6:363-366, in an attempt to develop a methodology for differential diagnosis of patients with non-allergic rhinitis, evaluated patients with rhinitis and negative skin tests, (taken to mean that their rhinitis had a non-allergic etiology), for cause of the rhinitis. Nasal smears from these patients were obtained by rolling a swab with nasal secretions on a glass slide, fixing with methanol, staining with Camaco stain (Wright-Giemsa stain), and counting the number of eosinophils per 100 cells. Sinus X-rays were conducted to detect sinusitis. NARES, non-allergic rhinitis with eosinophilia syndrome, is clinically defined in the paper as "nasal congestion/rhinorrhea with negative allergy skin tests, normal serum IgE, and $\geq 5\%$ eosinophils in the nasal smear." The purpose of the study was "to attempt to corroborate NARES as a new syndrome and to attempt to further classify and clarify non allergic rhinitis." There was no discussion in this paper regarding the problem of misidentification of this clinical condition with upper respiratory tract infections, and use of reagent test strips as part of the differential diagnosis is neither disclosed nor suggested.

Brofeldt, et al., *Biochemical Analysis of Nasal Secretions induced by Methacholine, Histamine, and Allergen Provocations*, Am. Rev. Respir. Dis. 1986; 133:1138-1142, obtained methacholine, histamine and allergen induced nasal secretions from subjects over a fifteen minute post-induction period. The nasal secretions were weighed and tested for hexose content (orcinol method), protein content (Lowry method), carbohydrate (gas liquid chromatography), sialic acid (colorimetric thiobarbituric acid assay), inorganic sulphate (radioactive BaCl_2), DNA (diphenylamine), albumin and immunoglobulins (rocket immunoelectrophoresis or ELISA). The different inducers were found to have differential effects on the various elements tested. However, there was no concomitant study of nasal secretions from patients suffering from an infection nor was the use of reagent test strips taught or suggested.

Eggelston, et al., *Mediators of Immediate Hypersensitivity in Nasal Secretions during Natural Colds and Rhinovirus Infection* Acta Otolaryngol. 1984; suppl. 413:25- 35, note that "[v]iral respiratory infections and allergic rhinitis have many similarities. Not only are symptoms similar in the two conditions, but the pathologic anatomy of both is dominated by vascular dilatation and edema with minimal cellular infiltrate in acute phases ..." The

authors postulated that these similarities are due to mast cell activation during infection, resulting in release of histamine. However, they report that spectrofluorometric analysis of histamine in nasal secretions of control subjects or patients with a natural cold or with a rhinovirus infection does not support this hypothesis. Histamine concentrations were found to be generally lower in individuals infected with influenza A or rhinovirus. TAME-esterase was also found not to be elevated during these infections. This article reports that during viral respiratory tract infection there is little or no esterase elevation, while in allergic rhinitis there is esterase elevation (see discussion at page 34 of the reference). However, the use of reagent test strips for this purpose is neither taught nor suggested, nor is there a discussion of how these results could be used in a differential diagnostic method also aimed at distinguishing sinusitis.

Baumgarten, *et al*, *Plasma Kallikrein During Experimentally Induced Allergic Rhinitis: Role in Kinin Formation and Contribution to TAME-Esterase Activity in Nasal Secretions*, J. Immunol. 1986; 137:977-982, report the observation that when allergic and non-allergic individuals are challenged intranasally with an allergen, post-challenge nasal lavages of only the allergic individuals contained elevated levels of immunoreactive human plasma kallikrein/prekallikrein (iHPK). This increase in iHPK correlated with increases in kinins, histamine, TAME-esterase, and clinical symptoms. In fact, these researchers argue that the TAME-esterase activity is produced by plasma kallikrein and mast cell tryptase. Thus, iHPK may be an additional marker that could be used in a reagent test strip for allergic rhinitis diagnosis. However, in this study, esterase was assayed by a radiochemical method and kinins were assayed using a radioimmunoassay, rather than by any type of reagent test strip.

Anderson *et al.*, *Mechanisms of nasal hyper-reactivity*, Eur. Arch. Otorhinolaryngol. 1995; 252 (suppl. 1):S22-S26, review the factors known to be involved in allergen-induced nasal hyper-reactivity. However, there is no teaching or suggestion of a method for distinguishing allergic from infection related rhinitis. Reagent test strips for this purpose are neither proposed nor suggested.

Florman, *et al.*, *Rapid Non-invasive Techniques for Determining Etiology of Bronchitis and Pneumonia in Infants and Children*, Clin. Chest Med. 1987; 8:669-679, provide a review of techniques for differential diagnosis of the causative agent in lower respiratory

tract infections. A number of rapid, non-specific and specific tests are mentioned. However, there is no mention of differential diagnosis of allergic from infective conditions and reagent test strips for this purpose are neither disclosed nor suggested.

- 5 Katz *et al.*, *A comparison of Imaging Techniques in Patients with Chronic Sinusitis* (X-Ray, MRI, A-Mode Ultrasound) *Allergy Proc.* 1995. 16:123-127, demonstrate the long-felt need for a rapid, inexpensive way to diagnose sinusitis and distinguish this condition from allergic rhinitis. The method of the instant invention has the potential for supplanting the much more expensive diagnostic techniques reported in this paper to be most reliable in
10 diagnosis of sinusitis (CAT scans and MRI).

Demoly *et al.*, *Assessment of Inflammation in noninfectious chronic maxillary sinusitis*, *J. Allergy Clin. Immunol.* 1994; 94:95-108, suggest that it might be possible to distinguish sinusitis (infection) from allergic rhinitis based on the contents of nasal mucosa. However,
15 the techniques used in attempting to distinguish these conditions depended on the use of immunohistochemistry of surgical specimens, immunocytochemistry of lavage fluids, and measurement of specific inflammatory mediators in sinus lavage fluids (ELISA, RIA). There is no teaching or suggestion that reagent dip-sticks could be used for this purpose.

- 20 Accordingly, there has been a long-felt need in the art for a rapid, inexpensive, non-invasive technique for a method capable of distinguishing between allergies and infections. The method of the instant invention involves testing nasal secretions with commercially available (Ames Division, Miles Laboratories, Inc., Elkhart, IN 46515) or novel or modified reagent test strips. The commercially available strips, also referred to as
25 dipsticks, test for pH, protein, glucose, ketone, white blood cell esterase, bilirubin and blood.

The following U.S. Patents which may be relevant to the instant invention are listed on the product insert of the Miles Laboratories Inc., reagent test strips, and are herein
30 incorporated by reference:

- 1) 3,438,737- Protein test composition and method of detecting proteins in fluids using the test composition.
- 2) 4,301,115- Test device having resistance to cross contamination between reactant areas and process for making it.

- 3) 4,637,979- Composition and test device for determining the presence of leukocytes containing a zwitterion coupling agent for determining the presence of leukocytes, esterase or protease in a sample.
- 4) 4,645,842- Pyrrole composition for detecting presence of hydrolytic analytes, useful in the detection of leukocytes, esterase and protease in a test sample.
- 5) 4,657,855- Composition and test device for determining the presence of leukocytes, esterase and protease in a test sample.
- 6) 4,704,460- Novel compounds for detecting the presence of hydrolytic analytes in a test sample which indicates the presence of leukocytes, esterase and protease in a test sample.
- 7) 4,758,508- Analytical process and agents for the detection of esterolytic and/or proteolytic enzymes in a liquid sample.

The following U.S. Patents which may be relevant to the instant invention are listed on the product insert or packaging of Boehringer Mannheim Corporation's reagent test strips, and are herein incorporated by reference:

- 1) 3,359,072- A protein determination method.
- 2) 3,418,079- A protein determination device and method.
- 3) 3,712,853- A nitrite detection reagent and method.
- 4) 3,897,214- A diagnostic device.
- 5) 3,802,842- A reagent test strip.
- 6) 4,013,416- A protein detection method.
- 7) 4,385,114- An oxidation indicator system.

However, none of these patents disclose or suggest a method for testing nasal mucous secretions to distinguish allergic from infectious conditions.

In the method of this invention, a sample of a patient's nasal secretions is tested and, based on the pH, amount of protein, nitrite and leukocyte esterase and eosinophils, it can quickly be determined if the patient is suffering from an allergy, a simple viral infection, or bacterial sinusitis. The method has the potential to supplant much more expensive and invasive clinical procedures.

Brief Summary of the Invention

This invention provides a method for rapidly, non-invasively and inexpensively differentiating between allergic rhinitis and respiratory viral or bacterial infections. The method involves measuring, for example by contacting a reagent test strip with a sample of nasal secretion, a series of agents in nasal secretions. The reagent test strip provides information on the pH, protein content, nitrite content, esterase activity and preferably also provides information on the level of eosinophil infiltration in the sample contacted, such that a combination of a pH between about 7.5 and 9, a moderately strong presence of protein, at least a trace of esterase and nitrite and little or no eosinophil infiltration indicates the presence of a bacterial infection (sinusitis). The combination of a pH between about 5.0 and 7.5, little or no protein, little or no esterase activity and little or no eosinophil infiltration, is an indication of viral infection (URI). However, the same profile as in URI viral infection but with clear indication of eosinophil infiltration is an indication of allergic rhinitis.

Also provided is a reagent test strip specifically adapted for rapidly, non-invasively and inexpensively differentiating between allergy and respiratory infection. The reagent test strip is adapted to provide information on the pH, protein content, nitrite content, esterase activity and eosinophil infiltration of the sample contacted, such that the method of this invention can quickly and easily be practiced.

Brief Summary of the Figures

Figure 1 shows the different chemical read-outs obtained by contacting reagent test strips with the nasal secretions of multiple patients presenting with respiratory discomfort. Closed circles (●) represent patients with radiologically proven sinusitis; open circles (○) represent patients having no sinusitis based on radiological investigation; open squares (□) represent patients with radiologically proven sinusitis that were at least partially treated with antibiotics prior to or during the evaluation period.

Figure 2 is a histogram based on the data shown in Figure 1 and a measure of eosinophil infiltration in the nasal exudates of the Figure 1 patients (not shown in Figure 1). From the raw data of Figure 1, a point system was established such that strong evidence of

eosinophil infiltration (+ + + eosinophil) received negative score of -6, moderate infiltration (+ + eosinophils) received a score of -4, and trace infiltration (+ eosinophils) received a score of -2; pHs greater than or equal to 8.5 received a score of +3, a pH between 8.0 and 8.4 received a score of +2, a pH between 7.25 and 7.9 received a score of +1 and a pH between 5.0 and 7.25 received a score of zero; protein content between about 30-100 mg/dl was given a score of +1; between about 100 mg/dl and 300 mg/dl was given a score of +2; protein between about 300 mg/dl and 2000 mg/dl was given a score of +3; and protein greater than 2000 mg/dl received a score of +4; low nitrite concentrations received a score of +1; moderate amounts of nitrite received a score of +2 and high amounts of nitrite received a score of +3; esterase activity in small amounts received a score of about +1, a score of +2 was assigned moderate amounts and a score of +3 was assigned to large amounts of esterase. By summing the scores assigned to eosinophils, pH, nitrite, protein, and esterase, the histogram of Figure 2 was produced. The level of eosinophil infiltration is shown in the figure by + , + + , and + + + for trace, moderate and strong eosinophil infiltration, respectively. Patients radiologically confirmed to have sinusitis are shown with stippled symbols; patients radiologically confirmed to have sinusitis but who had been at least partially treated with antibiotics are shown with a half filled half stippled symbol; patients radiologically clear of sinusitis but which exhibited eosinophilia are shown by open symbols; patients radiologically clear of sinusitis without concomitant eosinophilia are shown with diagonally filled/empty symbols.

Detailed Description of the Invention

This invention is a method for non-invasively, rapidly and simply distinguishing between allergies and infections which involves testing nasal secretions for the levels of a number of agents. Preferably the method comprises contacting nasal secretions with commercially available (for example, from Ames Division, Miles Laboratories, Inc., Elkhart, IN 46515, or from Boehringer Mannheim Corporation, Advanced Diagnostics, 9115 Hague Road, P.O. Box 50457, Indianapolis, IN 46250-0457) or novel specifically adapted reagent test strips. The commercially available strips, also referred to as dipsticks, typically test for pH, protein, nitrite glucose, ketone, white blood cell esterase, bilirubin and blood. In the method of this invention, a sample of a patient's nasal secretions is contacted with a reagent test-strip and, based on the pH, presence or absence of protein, levels of nitrite, esterase and a measure of eosinophil infiltration in the nasal secretion, it can quickly be determined

if the patient is suffering from an allergy or an infection. The method has the potential to supplant much more expensive and invasive clinical procedures. In the method of this invention, a commercially available reagent test-strip, or a novel, specifically adapted reagent test-strip, is contacted with a sample of a patient's nasal secretions. The patient
5 may be any mammal, including an animal or a human. Based on the differential read-out from the reagent test-strip, which preferably includes a measure of eosinophil infiltration, a determination can be made as to whether an allergy or an infection is responsible for upper-respiratory tract discomfort. With respect to commercially available reagent test-strips, those sold by the Ames Division of Miles Laboratories or the Boehringer Mannheim
10 Corporation are generally acceptable. These test-strips may be made as disclosed herein or as disclosed in any of U.S. Patent Nos. 3,438, 737, 4,301,115; 4,637,979. 4,645,842; 4,657,855; 4, 704,460; 4, 758,508; 3,359,072; 3,418,079. 3, 712,853; 3,897,214; 3,802,842; 4,013,416; and 4,385,114; all of which are incorporated by reference herein for this purpose. These reagent test-strips may be employed in the novel method of this
15 invention as further described hereinbelow with the additional requirement being that a measure of eosinophils must be made.

Accordingly, one embodiment of this invention is a simple method for distinguishing patients with allergies and patients with upper respiratory infections involves testing the
20 nasal secretions of these patients with reagent strips disclosed in the aforementioned patents. These dipsticks are inexpensive, and provide an indication of a contacted fluid's pH, protein, glucose, ketone, nitrite, esterase, bilirubin and blood content. The patient blows his/her nose on a receptacle (for
example wax paper or plastic film such as Saran Wrap or the like), or a swab of nasal
25 secretion is taken, and contacted with the test strip. The pH, protein, nitrite, and esterase contents are then evaluated based on the directions of the manufacturer found on the outside of the box in which the commercially available reagent test strips are sold. The procedure generally takes less than about sixty seconds. The following table provides results and the meaning thereof:

	Allergy	Viral Infection	Bacterial Infection (Sinusitis)
pH	5.0-7.5	7.5-9	7.5-9
Protein	Trace to +	Trace to +	++ or +++
Nitrite	Negative or trace	Negative or trace	++ or +++
Esterase	Negative or trace	Trace to +	++ or +++
Eosinophils	++ or +++	- or trace	- or trace

This data can be visualized by referring to Figure 1 which provides a graphic representation of the different chemical read-outs obtained by contacting reagent test strips with the nasal secretions of multiple patients presenting with respiratory discomfort.

- 5 Closed circles (●) represent patients with radiologically proven sinusitis; open circles (○) represent patients having no sinusitis based on radiological investigation; open squares (□) represent patients with radiologically proven sinusitis that were at least partially treated with antibiotics prior to or during the evaluation period. As can be seen from Figure 1, there is a clustering in the data points for the pH, protein, nitrite and esterase contents of
- 10 patients with or without sinusitis.

To aid in the differential diagnosis of allergic rhinitis, viral URI and sinusitis, we have discovered that by assigning a point system to several parameters measured from the mucus secretions of the patients, delimited differential scattering of the patient populations

15 can be achieved with only a minor amount of overlap between patients having these various clinical conditions. Figure 2 is a histogram based on the data shown in Figure 1 and a measure of eosinophil infiltration in the nasal exudates of the Figure 1 patients (not shown in Figure 1). From the raw data of Figure 1, a point system was established such that strong evidence of eosinophil infiltration (+++ eosinophil) received negative score of

20 -6, moderate infiltration (++ eosinophils) received a score of -4, and trace infiltration (+ eosinophils) received a score of -2; pHs greater than or equal to 8.5 received a score of +3, a pH between 8.0 and 8.4 received a score of +2, a pH between 7.25 and 7.90 received a score of +1 and a pH between 5.0 and 7.25 received a score of zero; protein content between about 30-100 mg/dl was given a score of +1; between about 100 mg/dl and 300

25 mg/dl was given a score of +2; protein between about 300 mg/dl and 2000 mg/dl was given a score of +3 and protein greater than 2000 mg/dl received a score of +4; low nitrite concentrations received a score of +1; moderate nitrite concentrations received a score of

+2; high concentrations of nitrite received a score of +3; esterase activity in small amounts received a score of about +1, a score of +2 was assigned to moderate amounts and a score of +3 was assigned to large amounts of esterase. By summing the scores of the eosinophils, pH, nitrite, protein, and esterase, the histogram of Figure 2 was produced. The level of eosinophil infiltration is shown in the figure by +, ++, and +++ for trace, moderate and strong eosinophil infiltration, respectively. Patients radiologically confirmed to have sinusitis are shown with stippled symbols; patients radiologically confirmed to have sinusitis but who had been at least partially treated with antibiotics are shown with a half filled half stippled symbol; patients radiologically clear of sinusitis but which exhibited eosinophilia are shown by open symbols; patients radiologically clear of sinusitis without concomitant eosinophilia are shown with diagonally filled/empty symbols. This method of differential diagnosis can be used with any method of collecting the pH, protein, esterase, nitrite and eosinophil content of nasal secretions, and is not restricted to the use of reagent indicator strips. The use of reagent indicator strips is, however, one of the most easily conducted, inexpensive and rapid methods for achieving this analysis.

The level of eosinophil infiltration is easily estimated in one embodiment of the invention using high power field microscopy (about 400 x magnification) by determining the percentage of total cells that are eosinophils in a Hansel's stained smear of nasal secretion. Accordingly, a 0-10% eosinophil profile received no negative score; a 10-25% eosinophil profile received a "+" (i.e. -2 assigned score); a 26-50% eosinophil profile received a "++" (i.e. -4 assigned score); and a 51-75% eosinophil profile received a "+++" (i.e. an assigned score of -6).

According to the package insert of the AMES 9SG Multistix® product. the following information, supplied for urinalysis by that manufacturer, may be directly applied to the novel utility disclosed and claimed herein, and is hereby incorporated as follows:

REAGENT STRIPS for mucus analysis are firm plastic strips to which are affixed several separate reagent areas. Depending on the product being used, AMES REAGENT STRIPS provide tests for glucose, bilirubin, ketone (acetoacetic acid), specific gravity, blood, pH, protein, urobilinogen, nitrite, and leukocytes in urine. A user of these strips refers to the carton and bottle label for specific reagent areas on the product being used.

The reagent test areas on AMES REAGENT STRIPS are ready to use upon removal from the bottle and the entire reagent strip is disposable. The strips may be read visually, requiring no additional laboratory equipment for testing. Certain configurations of strips may also be read instrumentally, using the CLINITEK® family of Urine Chemistry
5 Analyzers and the appropriate Program Module or Program Card from AMES.

The directions must be followed exactly. Accurate timing is essential to provide optimal results. The reagent strips must be kept in the bottle with the cap tightly closed to maintain reagent reactivity. To obtain optimal results, it is necessary to use fresh mucus.

10

Chemical Principles of the Procedure:

pH: This test is based on a double indicator principle that gives a broad range of colors covering the entire urinary pH range. Colors range from orange through yellow and green
15 to blue.

Protein: This test is based on the protein-error-of-indicators principle. At a constant pH, the development of any green color is due to the presence of protein. Colors range from yellow for "Negative" through yellow-green and green to green-blue for "Positive"
20 reactions.

Nitrite: At the acid pH of the reagent area, nitrite in the nasal secretion reacts with p-arsanilic acid to form a diazonium compound. This diazonium compound in turn couples with 1,2,3,4-tetrahydrobenzo(h)quinolin-3-ol to produce a pink color. The intensity of the
25 pink color developed is used as the basis for assigning the nitrite concentration score as described above.

Leukocytes: Granulocytic leukocytes contain esterases that catalyze the hydrolysis of the derivatized pyrrole amino acid ester to liberate 3-hydroxy-5-phenyl pyrrole. This pyrrole
30 then reacts with a diazonium salt to produce a purple product. The intensity of the purple color developed is used to assign a value to esterase activity as described above.

REAGENTS (Based on dry weight at time of impregnation):

pH: 0.2% w/w methyl red; 2.8% w/w methyl red; 2.8% w/w bromthymol blue; 97.0% w/w non-reactive ingredients.

5

Protein: 0.3% w/w tetrabromphenol blue; 97.3% w/w buffer; 2.4% w/w nonreactive ingredients.

Nitrite: 1.4% w/w p-arsanilic acid; 1.3% w/w 1,2,3,4-tetrahydrobenzo-(h)-quinolin-3-ol;
10 10.8% w/w buffer; 86.5% w/w nonreactive ingredients.

Leukocytes: 0.4% w/w derivatized pyrrole amino acid ester; 0.2% w/w diazonium salt; 40.9% w/w buffer; 58.5% w/w nonreactive ingredients.

15 Those skilled in the art will recognize that other chemical components may be used for carrying out the method disclosed herein.

Recommended Procedures for Handling Reagent Strips: All unused strips must remain in the original bottle. Transfer to any other container may cause reagent strips to deteriorate
20 and become unreactive. Do not remove desiccant(s) from bottle. Do not remove strip from the bottle until immediately before it is to be used for testing. Replace cap immediately and tightly after removing reagent strip. Do not touch test areas of the reagent strip. Work areas and specimen containers should be free of detergents and other contaminating substances.

25

Dip test areas in mucus completely, but briefly, to avoid dissolving out the reagents. If using strips visually, read test results carefully at the times specified, in a good light (such as fluorescent) and with the test area held near the appropriate Color Chart on the bottle label. Do not read the strips in direct sunlight. If the strips are used instrumentally,
30 carefully follow the directions given in the appropriate instrument operating manual. Protection against ambient moisture, light and heat is essential to guard against altered reagent.

Discoloration or darkening of reagent areas may indicate deterioration. If this is evident, or if test results are questionable or inconsistent with expected finding, the following steps are recommended: (1) confirm that the product is within the expiration date shown on the label; (2) check performance against known positive control materials (e.g., CHEK-STIX® Control Strips); (3) retest with fresh product.

The following procedure should be followed exactly to achieve reliable test results:

1. Collect fresh mucus specimen on a non-absorbent surface.
2. Remove one strip from the bottle and replace cap. Completely immerse reagent areas of the strip in fresh mucus and remove immediately to avoid dissolving out reagents.
3. If reading visually, compare reagent areas to corresponding Color Chart on the bottle label at the time specified. Hold strip close to color blocks and match carefully. Avoid laying the strip directly on the Color Chart, as this will result in soiling the chart.
4. If reading instrumentally, carefully follow the directions given in the appropriate instrument operating manual.

Proper read time is critical for optimal results. If using strips visually, read the pH, protein, and nitrite at 60 seconds; and leukocytes at 2 minutes. The pH and protein areas may also be read immediately or at any time up to 2 minutes after dipping.

After dipping the strip, check the pH area. If the color on the pad is not uniform, read the reagent area immediately, comparing the darkest color to the appropriate Color Chart. All reagent areas except leukocytes may be read at about 1 minute for identifying negative specimens and for determination of the pH. A positive reaction (small or greater) at less than 2 minutes on the leukocyte test may be regarded a positive indication of leukocytes. Color changes that occur after 2 minutes are of no diagnostic value. If using strips instrumentally, the instrument will automatically read each reagent area at a specified time.

For best results, performance of reagent strips should be confirmed by testing known negative and positive specimens or controls whenever a new bottle is first opened. Negative and positive specimens or controls may also be randomly hidden in each batch of specimens tested. Each laboratory should establish its own goals for adequate standards of performance, and should question handling and testing procedures if these standards are

not met. CHEK-STIX® Urinalysis Control Strips (#1360) from AMES®, with positive or defined results, provide a convenient basis for quality control program.

Results with AMES REAGENT STRIPS are obtained in clinically meaningful units directly from the Color Chart comparison when using strips visually. With instrumental use, the reagent pads are "read" by the instrument and the results are displayed or printed. The color blocks and instrumental display values represent nominal values; actual values will vary around the nominal values.

10 pH: If proper procedure is not followed and excess mucus remains on the strip, a phenomenon known as "runover" may occur, in which the acid buffer from the protein reagent will run onto the pH area, causing a false lowering of the pH result.

Protein: Contamination of the nasal secretion specimen with quaternary ammonium compounds (e.g., from some antiseptics and detergents) or with skin cleansers containing chlorhexidine may also produce false positive results.

Nitrite: Pink spots or pink edges should not be interpreted as a positive result. Any degree of uniform pink color development should be interpreted as a positive nitrite test.

20 Leukocytes: Elevated glucose concentrations (≥ 3 g/dl) or high specific gravity may cause decreased test results. The presence of cephalexin (Keflex®), cephalothin (Keflin®), or high concentrations of oxalic acid may also cause decreased test results. Tetracycline may cause decreased reactivity, and high levels of the drug may cause a false negative reaction.

25 Leukocytes: Normal nasal secretion will generally yield negative results; positive results (small or greater) are clinically significant. Individually observed trace results may be of questionable clinical significance; however, trace results observed repeatedly may be clinically significant. Positive and repeated trace results indicate the need for further testing of the patient and/or nasal specimen, according to medically accepted procedures.

30 Specific Performance Characteristics: Specific performance characteristics are based on clinical and analytical studies. In clinical specimens, the sensitivity depends upon several factors: the variability of color perception; the presence or absence of inhibitory factors,

the specific gravity, and the pH; and the lighting conditions when the product is read visually. Because the color of each reagent area changes as the analyte concentration increases, the percentage of specimens detected as positive will increase with the analyte concentration.

5

Each color block or instrumental display value represents a range of values. Because of specimen and reading variability, specimens with analyte concentrations that fall between nominal levels may give results at either level. Exact agreement between visual results and instrumental results might not be found because of the inherent differences between the

10 perception of the human eye and the optical system of the instruments.

pH: The pH test area measure pH values generally to within 1 unit in the range of 5-8.5 visually and 5-9 instrumentally.

15 Protein: The reagent area is more sensitive to albumin than to globulins, hemoglobin, Bence-Jones Protein and mucoprotein; a negative result does not rule out the presence of these other proteins.

Nitrite: Comparison of the reacted reagent area against a white background may aid in the
20 detection of low levels of nitrite ion, which may otherwise be missed.

Availability: AMES REAGENT STRIPS for Urinalysis are available in bottles of 100 strips: MULTISTIX® 10 SG (#2300A); MULTISTIX® 9 (#2301A); MULTISTIX® 9 SG (#2303A); MULTISTIX® 8 SG (#2304A); MULTISTIX® 7 (#2305A); N-MULTISTIX®
25 SG (#2740A); MULTISTIX® SG (#2741A); N-MULTISTIX® (#2829A); MULTISTIX® (#2820A); and BILI-LABSTIX® (#2814A).

Any of these or other commercially available reagent test strips which provide pH, protein, nitrite, esterase and preferably also eosinophil data can be used according to this disclosure
30 to differentiate between bacterial infections, viral infections and allergic conditions. Thus, in a fashion completely analogous to that described above for the Ames REAGENT STRIPS, commercially available reagent test strips produced by Boehringer Mannheim Corporation may be used or adapted for this purpose. For example CHEMSTRIP 9, Catalog No. 417109, provides a readout for leukocytes, nitrite, pH, protein and several

other analytes. The information provided in the package insert for the CHEMSTRIP 6, 7, 8, 9, 10 (which also provides a readout for specific gravity), is largely analogous to the information provided hereinabove from the Multistix® product. In our hands, testing of nasal secretions using the Boehringer product yielded results which, according to this invention, are similar to those obtained using the Multistix® product. Slight adjustments in the color readouts and values thereof may be needed due to the differences between the color charts used by the two manufacturers, but, based on the instant disclosure, those skilled in the art are able to make any necessary adjustments.

10 In one aspect of the invention, there is provided a reagent test strip specifically adapted for rapidly, non-invasively and inexpensively differentiating between allergic conditions and respiratory, viral and bacterial infections. In use, the test strip is optimized to provide information about nasal mucus secretions including, but not limited to, the pH, protein content, nitrite, esterase activity and level of eosinophil infiltration, such that all of the information presented in Figure 2 can be obtained from a single indicator strip. This is achieved, for example, by preparing a reagent test strip according to commercially available strips, but in addition, providing a means for measuring the amount of eosinophil cationic protein (ECP) or another eosinophil specific protein or enzyme present in the nasal secretion, the presence of which is proportional to the amount of eosinophil infiltration.

15 Alternatively, the test strip could be made so as to selectively trap eosinophils, and the assay could then be for any substance found in eosinophils (such as an enzyme or any other detectable substance), without it being necessary for the substance to be specific for eosinophils. The novel reagent test strip of this invention, therefore, can include an indicator location on the strip comprising immobilized eosinophil cationic protein (ECP) or other appropriate protein bound to labeled anti-ECP antibody or other specific antibody. In this event, the strip is contacted with mucus from a patient and all of the other parameters, (pH, protein, nitrite, esterase) are read from the strip. The strip is then incubated for a sufficient amount of time so that ECP present in the mucus, due to eosinophil infiltration, competes the labeled antibody from the strip-bound ECP. As a result, upon visualization of the label, the greater the amount of ECP present in the mucus, the lower the amount of label visualized. The antibody could be enzymatically labeled, or labeled with biotin or avidin, which could then be visualized by methods well known in the art. Analogously, ECP or other eosinophil antigen specific antibody could be immobilized on the strip which, upon exposure to nasal secretions, binds any ECP or other eosinophil specific protein or

enzyme present in the secretion. Excess sample could then be washed from the strip and a second, labeled ECP or other eosinophil antigen specific antibody or chromogenic eosinophil specific enzyme substrate could be contacted with the strip. In this case, the greater the signal upon development, the greater the amount of eosinophilia in the patient.

5 Preferably, an eosinophil specific enzyme is detected by providing a chromogenic reagent on the strip which changes color to an extent proportional to the amount of eosinophils present in the sample. In this context, the teachings of U.S. Patent Nos. 5,369,007 and 5,200,321, herein incorporated by reference, while directed to a very different art (detection of illicit drugs) are instructive here. According to those patents, a microassay on

10 a card could be adapted to the instant utility in either a displacement or competition mode, as described herein above, using eosinophil specific antigens and antibodies. Likewise, the concepts and methods disclosed therein could be utilized to prepare the novel reagent test strip of the instant invention. In yet another embodiment of the novel test strip of this invention, a portion of the strip contacted with the nasal secretion is transparent. This

15 portion is then simply stained and quantitated microscopically for eosinophils as described hereinabove, after reading all of the other reagent parameters.

In any event, even with the use of a standard, commercially available reagent test strip, all that is required for the method of this invention is that, in addition to contacting the nasal

20 secretion with an appropriate reagent test strip and quantitation of the pH, nitrite, esterase and protein, is that the mucus be evaluated for eosinophils. This is quickly and easily achieved by making a smear of the nasal secretion, staining the smear with eosine or other appropriate dye, and quantitating the number of eosinophils present per field. Alternatively, the hemocytometric method of Okuda *et al.* (*Int Arch Allergy Immunol.*

25 [1994] 104:6) or of Settipane (*Allergy Proc.* [1985] 6:303-366), herein incorporated by reference, could be used for this purpose.

According to methods known in the art, nasal ECP has been found to range between about 30 ng/ml in a "normal" individual, up to about 200 ng/ml in individuals experiencing acute

30 allergic reactions (see Clin. Exp. Allergy, 1997, 27:270-276; see also JACI 1996, 97:104-112; see also Clin. Exp. Allergy 1994, 24:1151-1156). Commercially available antibodies for carrying out the method and for making the device according to the present invention may be obtained, for example, from Pharmingen. Thus, Pharmingen catalog number 15371A is a mouse IgG1 monoclonal antibody (clone AHE-1) which recognizes human

eosinophil peroxidase, an 81 kD granule protein specific to eosinophils. Pharmingen catalog number 15381A is a mouse IgG1 monoclonal antibody (clone AHE-2) which recognizes human eosinophil Major Basic Protein, a 14 kD granule protein specific to eosinophils. Accordingly, a wide variety of eosinophil specific markers may be employed according to the method and for the device of this invention. Thus, a protein selected from the group, but not limited to the group, eosinophil Major Basic Protein (MBP), present at about 9 µg/million eosinophils, eosinophil cationic protein (ECP), present at about 5 µg/million eosinophils, eosinophil derived neurotoxin (EDN), present at about 3 µg/million eosinophils, or eosinophil peroxidase (EPO), present at about 12 µg/million eosinophils, (see Textbook of Allergy, Principles and Practice, for concentrations of these markers), may be employed in the device or method according to this invention, using commercially available antibody, or antibody developed independently. As mentioned above, avidin/biotin conjugates of such eosinophil specific markers may also be employed according to this invention.

15

Accordingly, this invention provides a method for rapidly, non-invasively and inexpensively differentiating between allergy and viral or bacterial respiratory infection. The method involves measuring the pH, protein content, nitrite content, esterase activity and eosinophil content of a sample of contacted nasal secretion. A combination of a pH between about 7.5 and 9, a moderately strong presence of protein, and at least a trace of nitrite and esterase and the absence of eosinophils indicates the presence of a bacterial infection. The combination of a pH between about 5.0 and 7.0, little or no protein, little or no nitrite, little or no esterase activity and moderate to strong eosinophil content is indicative of an allergic condition. The combination of a pH between about 5.0 and 7.0, little or no protein, and at least a trace of nitrite and esterase and the absence of eosinophil infiltration indicates an upper respiratory tract viral infection. In a preferred embodiment of this method, each value obtained for pH, protein, nitrite, esterase, and eosinophil infiltration in a patient's nasal secretion, is assigned a value such that the sum of assigned values results in an enhancement in the clustering of patients having bacterial infections, a clustering of patients having viral infection, and a clustering of patients having allergies. At the same time the assigned values preferably result in a separation of these clusters from each other. In a preferred embodiment, this method is practiced with a reagent test strip. The test strips which are used in this testing may be those produced by the Ames division of Miles laboratory as disclosed in any of U.S. Patent Nos. 3,438, 737. 4,301,115;

4,637,979; 4,645,842; 4,657,855; 4,704,460; 4,758,508, or by Boehringer Mannheim Corporation, as disclosed in any of U.S. Patent Nos. 3,359,072; 3,418,079; 3,712,853; 3,897,214; 3,802,842; 4,013,416; 4,385,114. A reagent test strip specifically adapted for rapidly, non-invasively and inexpensively differentiating between allergy and respiratory
5 infection is also provided. This novel strip comprises reagents adapted to provide information on the pH, protein content, nitrite content, esterase activity and eosinophil content of the sample contacted.

References

Service, R.F. (1995) *Science* 270:724- 727.

5

Katz, *et al.* (1995) *Allergy Proc.* 16:123-127.

Wang, *et al.* (1995) "Correlations between Complaints, Inflammatory Cells and Mediator Concentrations in Nasal Secretions after Nasal Allergen Challenge and during Natural Allergen Exposure," *Int. Arch. Allergy Immunology* 106:278-285.

10

Sigurs, *et al.* (1994) "Eosinophil cationic protein in nasal secretion and in serum and myeloperoxidase in serum in respiratory syncytial virus bronchiolitis: relation to asthma and atopy," *Acta Paediatr* 83:1151-1155.

15

Okuda, *et al.* (1994) " A Novel Method of Counting Eosinophils in Nasal Secretion of Allergic Rhinitis by Hemocytometric Method," *Int. Arch. Allergy Immunol.* 104 (suppl. 1):6.

20 Kowalski, *et al.* (1993) "Neutrophil chemotactic activity (NCA) in nasal secretions from atopic and nonatopic subjects," *Allergy* 48:409-414.

Igarashi, *et al.* (1993) " Analysis of nasal secretions during experimental rhinovirus upper respiratory infections," *J. Allergy Clin. Immunol.* 92:722- 731.

25

Sperber, *et al.* (1993) "*In vivo* detection of a novel macrophage-derived protein involved in the regulation of nasal mucus-like glycoconjugate secretion," *J. Allergy Clin. Immunol.* 92:581-588.

30 Knani, *et al.* (1992) "Indirect evidence of nasal inflammation assessed by titration of inflammatory mediators and enumeration of cells in nasal secretions of patients with chronic rhinitis," *J. Allergy Clin. Immunol.* 90:880-889.

Klementsson, *et al.* (1991) "Eosinophils, secretory responsiveness and glucocorticoid-induced effects on the nasal mucosa during a weak pollen season," *Clinical and Experimental Allergy* 21:705- 710.

- 5 Gordon, *et al.* (1991) "The pathophysiology of rhinitis," *J. Allergy Clin. Immunol.* 88:33-42.

Cohen, R.A, E.P. Brestel (1988) "Nasal secretory response to allergen provocation," *Clinical Allergy* 18:435-443.

10

Liu, *et al.* (1988) "Injurious effect of eosinophil extract on the human nasal mucosa," *Rhinology* 26:121-132.

- Anderson, *et al.* (1987) "Allergen-induced nasal hyperactivity appears unrelated to the size
15 of the nasal and dermal immediate allergic reaction," *Allergy* 42:631-637.

Settipane, G.A, D.E. Klein (1985) "Non Allergic Rhinitis: Demography of Eosinophils in Nasal Smear, Blood Total Eosinophil Counts and IgE Levels," *NER Allergy Proc.* 6:363-366.

20

Brofeldt, *et al.* (1986) "Biochemical Analysis of Nasal Secretions induced by Methacholine, Histamine, and Allergen Provocations," *Am. Rev. Respir. Dis.* 133:1138-1142.

- 25 Eggelston, *et al.* (1984) "Mediators of Immediate Hypersensitivity in Nasal Secretions during Natural Colds and Rhinovirus Infection," *Acta Otolaryngol.* suppl. 413:25-35.

Baumgarten, *et al.* (1986) "Plasma Kallikrein During Experimentally Induced Allergic Rhinitis: Role in Kinin Formation and Contribution to TAME-Esterase Activity in Nasal
30 Secretions," *J. Immunol.* 137:977-982.

Anderson, *et al.* (1995) "Mechanisms of nasal hyper-reactivity," *Eur. Arch. Otorhinolaryngol.* 252 (suppl. 1):S22-S26.

Florman, *et al.* (1987) "Rapid Non-invasive Techniques for Determining Etiology of Bronchitis and Pneumonia in Infants and Children," *Clin. Chest Med.* 8:669-679.

Katz, *et al.* (1995) "A comparison of Imaging Techniques in Patients with Chronic
5 Sinusitis (X-Ray, MRI, A-Mode Ultrasound)," *Allergy .Proc.* 16:123-127.

Demoly, *et al.* (1994) " Assessment of Inflammation in noninfectious chronic maxillary sinusitis," *J. Allergy Clin. Immunol.* 94:95-108.

10 Atkinson, Roger Lee, Marshall Lloyd Fader, U.S. Patent No. 3,438,737, issued April 15, 1969.

Rapkin, Myron C., David L. Tabb, U.S. Patent No. 4,301,115, issued November 17, 1981.

15 Skjold, A. Christopher, Herbert Hugl, Gerhard Wolfrum, U.S. Patent No. 4,637,979, issued January 20, 1987.

Corey, Paul F., U.S. Patent No. 4,645,842, issued February 24, 1987.

20 Corey, Paul F., Christopher Skjold, James H. Pendergrass, Lonnie Stover, U.S. Patent No. 4,657,855, issued April 14, 1987.

Corey, Paul F., U.S. Patent No. 4, 704,460, issued November 3, 1987.

25 Schnabel, Eugen, James Travis, A. Christopher Skjold, U.S. Patent No. 4,758,508, issued July 19, 1988.

Kidwell, David A, U.S. Patent No. 5,369,007. issued November 29, 1994.

30 U.S. Patent No. 5,200,321

Rey, Hans-Georg, Peter Rieckmann, U.S. Patent No. 3,359,072, issued December 19, 1967.

Rey, Hans-Georg, Peter Rieckmann, U.S. Patent No. 3,418,079, issued December 24, 1968.

Rittersdorf, Walter, Hans-Georg Rey, Peter Rieckmann, U.S. Patent No. 3, 712,853, issued
5 January 23, 1973.

Lange, Hans, Walter Rittersdorf, Hans-Georg Rey, U.S. Patent No. 3,897,214, issued July 29, 1975.

10 Lange, Hans, Walter Rittersdorf, Hans-Georg Rey, Peter Rieckmann, U.S. Patent No. 3,802,842, issued April 9, 1974.

Rittersdorf, Walter, Werner Güthlein, Wolfgang Werner, Hans-Georg Rey, Peter Rieckmann, U.S. Patent No. 4,013,416, issued March 22, 1977.

15

Güthlein, Werner, Walter Rittersdorf, Hugo Tiedemann, Peter Vogel, Wolfgang Werner, U.S. Patent No. 4,385,114, issued May 24, 1983.

What Is Claimed Is:

1 1. A method for differentiating between allergic rhinitis, upper respiratory tract viral
2 infection and bacterial sinusitis, which comprises measuring a sample of a patient's nasal
3 secretion, for pH, protein content, nitrite content, esterase activity and eosinophil counts of
4 the sample, such that a combination of:
5 (a) a pH between about 7.5 and 9, a moderately strong presence of protein, at least a
6 trace of nitrite and esterase, and low or absent eosinophil counts is indicative of bacterial
7 sinusitis;
8 (b) a pH between about 5.0 and 7.0, little or no protein, little or no nitrite, little or no
9 esterase activity and moderate to high eosinophil counts is indicative of allergic rhinitis;
10 and
11 (c) a pH between about 5.0 and 7.0, little or no protein, at least a trace of nitrite and
12 esterase and low or absent eosinophil counts indicates an upper respiratory tract viral
13 infection.

1 2. The method of claim 1 wherein for each measurement obtained for pH, protein,
2 nitrite, esterase, and eosinophil counts in a patient's nasal secretion, an arbitrary clinical
3 score is assigned such that by summing and graphing the clinical score assigned for each
4 measurement to produce a graph of said clinical scores, a first grouping of clinical scores
5 for patients having bacterial sinusitis occurs, a second grouping of clinical scores for
6 patients having upper respiratory tract viral infection occurs, and a third grouping of
7 clinical scores for patients having allergic rhinitis occurs, such that said graph separates
8 said first, said second and said third grouping of clinical scores.

1 3. The method of claim 1 wherein said method is practiced with a reagent test strip.

1 4. A method for differentiating between viral infectious rhinitis, bacterial sinus
2 infection and allergic rhinitis in a patient, which comprises:
3 (a) contacting nasal secretion from said patient with a reagent test strip adapted for
4 providing measurements of eosinophil, protein, pH, nitrite, and esterase
5 concentrations of the secretion, wherein said reagent test strip is adapted to provide
6 said measurements by providing reactants on said reagent test strip which

- 7 specifically indicate eosinophil, protein, pH, nitrite, and esterase concentrations
8 upon contact of said nasal secretion with said reactants;
- 9 (b) measuring the pH, protein content, nitrite content, esterase activity and eosinophil
10 concentration of said nasal secretion such that a combination of:
- 11 (i) a pH between about 7.5 and 9, a moderately strong presence of protein, at
12 least a trace of nitrite and esterase, and low or absent eosinophil counts is
13 indicative of bacterial sinusitis;
- 14 (ii) a pH between about 5.0 and 7.0, little or no protein, little or no nitrite, little
15 or no esterase activity and moderate to high eosinophil counts is indicative
16 of allergic rhinitis;
- 17 (iii) a pH between about 5.0 and 7.0, little or no protein, at least a trace of nitrite
18 and esterase and low or absent eosinophil counts indicates an upper
19 respiratory tract viral infection; and
- 20 (c) correlating the results obtained from said measuring with a control.

1 5. The method according to claim 1 which comprises contacting and measuring nasal
2 secretion from said patient with a urinalysis reagent test strip, which measures protein,
3 pH, nitrite, and esterase concentrations of the secretion, wherein said reagent test strip
4 is adapted to in addition provide a measurement of the eosinophil concentration of said
5 nasal secretion.

1 6. The method according to claim 1 which comprises:


- 2 (a) contacting and measuring nasal secretion from said patient with a urinalysis reagent
3 test strip, which measures protein, pH, nitrite, and esterase concentrations of the
4 secretion; and
- 5 (b) measuring eosinophil concentration of said nasal secretion.

1 7. A device for differentiating between allergic rhinitis, upper respiratory tract viral
2 infection and bacterial sinusitis, comprising a support upon which is fixed discrete
3 indicators of pH, protein content, nitrite content, esterase activity, and eosinophil
4 content of a sample with which said reagent test strip is contacted.


1 8. The device according to claim 7 configured as a reagent test strip.

- 1 9. The device according to claim 8 comprising an immobilized eosinophil specific
2 protein.
- 1 10. The device according to claim 9 wherein said protein is selected from the group
2 consisting of eosinophil Major Basic Protein, eosinophil cationic protein, eosinophil
3 derived neurotoxin, eosinophil peroxidase, and mixtures thereof.
- 1 11. The device according to claim 10 wherein said protein is bound to a labeled or unlabeled
2 avidin, biotin, or antibody.
- 1 12. The device according to claim 8 comprising an immobilized antibody specific to an
2 eosinophil specific antigen.
- 1 13. The device according to claim 12 wherein said antibody is specific to a protein selected
2 from the group consisting of eosinophil major basic protein, eosinophil cationic
3 protein, eosinophil derived neurotoxin, eosinophil peroxidase, and mixtures thereof.
- 1 14. The device according to claim 8 comprising an immobilized substrate which upon
2 contact with an eosinophil specific enzyme is converted to a detectable reaction
3 product.
- 1 15. The device according to claim 14 wherein said substrate is a chromogenic substrate.

1/2



Sinusitis
Figure 1



Scores
Figure 2

INTERNATIONAL SEARCH REPORT

Inter Application No

PCT/US 99/05751

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12Q1/44 G01N33/68 G01N33/84

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12Q G01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
E	US 5 910 421 A (SMALL JR PARKER A ET AL) 8 June 1999 (1999-06-08) the whole document ---	1-15
A	RAPHAEL GD ET AL: "The pathophysiology of rhinitis. V. Sources of protein in allergen-induced nasal secretions" J. ALLERGY CLIN. IMMUNOL., vol. 88, no. 1, July 1999 (1999-07), pages 33-42, XP000852998 cited in the application abstract --- -/--	1-15

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

25 November 1999

Date of mailing of the international search report

07/12/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Pellegrini, P

INTERNATIONAL SEARCH REPORT

Inter Application No

PCT/US 99/05751

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	LANS DM ET AL: "Nasal eosinophilia in allergic and nonallergic rhinitis: usefulness of the nasal smear in the diagnosis of allergic rhinitis" ALLERGY PROC, vol. 10, no. 4, August 1989 (1989-08), pages 275-280, XP000852703 abstract ---	1-15
A	NACLERIO R M ET AL: "Mediator release after nasal airway challenge with allergen." AMERICAN REVIEW OF RESPIRATORY DISEASE, (1983 OCT) 128 (4) 597-602. , XP000852716 abstract ---	1-15
A	US 4 645 842 A (COREY PAUL F ET AL) 24 February 1987 (1987-02-24) cited in the application column 3, line 51-54 column 21, line 19-22 -----	1-15

INTERNATIONAL SEARCH REPORT

information on patent family members

Inter Application No
PCT/US 99/05751

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
US 5910421	A	08-06-1999	NONE	
US 4645842	A	24-02-1987	AT 64382 T	15-06-1991
			AU 558425 B	29-01-1987
			AU 4072485 A	10-10-1985
			CA 1267500 A	03-04-1990
			EP 0157327 A	09-10-1985
			ES 541871 A	16-06-1986
			FI 851356 A,B,	07-10-1985
			IE 57919 B	19-05-1993
			IL 74645 A	31-10-1988
			JP 1436349 C	25-04-1988
			JP 60260558 A	23-12-1985
			JP 62041710 B	04-09-1987
			NO 851226 A	07-10-1985
			US 4774340 A	27-09-1988
			US 4704460 A	03-11-1987